Please use this identifier to cite or link to this item:
Title: Pharmacogenetic testing: Legal considerations for consent, privacy and disclosure
Authors: Romeo Malanda, Sergio 
Nicol, Dianne
UNESCO Clasification: 32 Ciencias médicas
Keywords: Consent
Duty of confidentiality
Exceptional circumstances
Pharmacogenetic testing, et al
Issue Date: 2008
Publisher: 1741-0541
Journal: Personalized Medicine 
Abstract: This review provides an overview of the European legal framework relating to the protection of sensitive data obtained from pharmacogenetic tests. The primary objective of pharmacogenetic testing is neither diagnosis nor prediction of disease, but determining likely responses to medicines based on specific genetic factors. Nevertheless, pharmacogenetic testing can lead to the disclosure of sensitive information and, as a consequence, it is argued that consent is a prerequisite. It is further argued that appropriate protection for privacy and confidentiality is crucial, but that disclosure may be justified in certain exceptional circumstances. This article describes the various European legislative instruments that provide useful guidance on the types of circumstances when disclosure may be justified.
ISSN: 1741-0541
DOI: 10.2217/17410541.5.2.155
Source: Personalized Medicine [ISSN 1741-0541], v. 5, p. 155-161
Appears in Collections:Artículos
Show full item record


checked on Sep 18, 2022

Page view(s)

checked on May 21, 2022

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.